Developer docs
API playgroundTry for free, no card

Search company profiles

Swiss Stem Cell Foundation

Full company profile

uuid005d9fl

Namestring
Swiss Stem Cell Foundation
Legal namestring
Swiss Stem Cell Foundation
Websiteurl
sscf.ch
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Swiss Stem Cell Foundation (SSCF) is an independent, non-profit foundation established in 2009 in Lugano, Switzerland, with a research laboratory in Vacallo. It pursues research and development in adipose-derived mesenchymal stem cells (MSCs) and stromal vascular fraction (SVF), with the goal of developing new cell therapies for human medical use. Its core technical assets include GMP-compliant protocols for processing adipose tissue, MSC cryopreservation offering up to 30-year storage, MSC expansion for clinical use, exosome production and characterization, and the SSCF Research Biobank authorized by the Canton Ticino Ethics Committee (Rif. CE 2961). Notable scientific output includes a 2018 Nature publication (with EPFL and ETH Zurich) on aReg cells and twelve peer-reviewed publications in Medline-indexed journals; a China-granted patent covers the adipose tissue extraction process, and the SSCF brand is trademarked in the EU and China.

SSCF operates a hybrid GTM in which research services, GMP-compliant cell production, and cryopreservation services are delivered to surgical and clinical specialists (plastic surgeons, orthopedists, regenerative medicine practitioners), while international research collaborations with EPFL, ETH Zurich, Politecnico di Torino, Aix-Marseille University, University of Insubria, and IRCCS Besta distribute expertise and build scientific credibility. Revenue is generated through professional services (research and consultancy), GMP cryopreservation services, Academy training courses (CHF 450 per participant), and donations (with Certificates of Donation issued). The foundation runs the annual iCAST congress series since 2015 (9 editions) and Academy hands-on training programs at partner clinics (Clinique Genolier, Clinique Sant'Anna).

Major upcoming capacity is the Regenerative Medicine Institute — a 3,300 sqm applied research facility in the Lugano hospital district scheduled for completion by end of 2025, designed to accommodate GMP clean rooms, genetics labs, diagnostics labs, biobanking facilities, and lab space for approximately 50 researchers. The foundation is governed by a Board of Foundation Members and a Scientific Committee, with Dr. Gianni Soldati serving as President and Director of Research.

Short descriptiontext

Swiss Stem Cell Foundation is a non-profit research foundation (est. 2009, Lugano, ~10 employees) that develops GMP-compliant adipose-derived stem cell therapies, operates an ethics-committee-authorized biobank, and delivers research services, cryopreservation, training courses, and the annual iCAST congress to clinicians and academic partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLugano, Switzerland
HQ citystring
Lugano
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Stem cell research, Regenerative medicine, Cell therapy services, GMP cell processing, Medical research education
Industry3 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYBPAGAKAA
Private Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Grantmaking Foundations813211
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Educational Services8200
Product category
Regenerative Medicine Research
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Research services and consultancy
TypeProfessional Services
Description

Provision of services in analysis and research domains, including consultancy through qualified professionals on new products, tools, medical devices, and therapies. As a non-profit foundation, revenues support research and development activities.

sscf.ch
2GMP cryopreservation services
TypeProfessional Services
Description

Cryopreservation of adipose-derived mesenchymal stem cells as a service for future medical needs, including GMP-compliant processing of SVF for clinical use.

sscf.ch
3Education and training programs
TypeProfessional Services
Description

Organization and delivery of Academy courses and professional training for healthcare operators on stem cell therapies and adipose tissue handling. Course fees (e.g., CHF 450 per participant) contribute to operational funding.

sscf.ch
4Donations and charitable contributions
TypeSubscription Recurring
Description

The foundation accepts donations to support stem cell research and development of new stem cell therapies, issuing Certificates of Donation to contributors.

sscf.ch
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Others, Marketing or Sales
Pricing details1 tier
1Academy training course fee
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CHF 600 course cost minus CHF 150 discount = CHF 450 total per participant. Course covers adipose tissue harvesting and preparation for regenerative medicine.

sscf.ch
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1SSCF
Description

Abbreviated name used for Swiss Stem Cell Foundation in communications and materials.

sscf.ch
+1 more record
Core offering1 text field

The Swiss Stem Cell Foundation is an independent non-profit foundation pursuing research and development in stem cells, focused on adipose-derived mesenchymal stem cells (MSCs) and stromal vascular fraction (SVF). It provides GMP-compliant isolation, characterization, cryopreservation, and expansion services for MSCs, operates an ethics-committee-authorized research biobank, and develops new cell therapies for human medical use. The foundation also delivers professional training through its Academy program and disseminates knowledge via the annual iCAST international congress on adipose stem cell treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 364 GMP-compliant SVF productions across multiple centers in a standardization study
+1 more record
Product overview1 text field

The Swiss Stem Cell Foundation operates as a non-profit research foundation offering a portfolio of stem cell research and development services. The core offering centers on the SSCF Research Biobank for sample storage and the GMP-compliant production of mesenchymal stem cell products and adipose-derived stromal vascular fraction for cell therapies. Additional services include MSC cryopreservation, expansion for clinical use, and exosome characterization. The Foundation organizes the annual iCAST Congress Series (International Congress on Adipose Stem Cell Treatments) since 2015 and Academy training programs for professionals. A major upcoming development is the Regenerative Medicine Institute—a 3,300 sqm facility with GMP laboratories, biobanking spaces, and conference facilities planned for completion in 2025.

Product and service1 record
1SSCF Research Biobank
Description

Research biobank authorized by the Canton Ticino Ethics Committee (Ref CE 2961) providing pre-clinical research services including collection, storage, and characterization of mesenchymal stromal/stem cell samples from adipose tissue. Enables development of methodologies and technologies for isolation, characterization, and large-scale production of mesenchymal stromal/stem cells for research projects and future cell therapies in human medicine.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Bart Deplancke's Laboratory of Systems Biology and Genetics at EPFL. Joint project on single-cell characterization of SVF populations and sub-populations. Resulted in Nature publication (2018) on aReg cells. Ongoing collaboration for characterization of substances produced by aReg cells.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborated with ETH Zurich alongside EPFL in the identification of aReg cell populations in adipose tissue (Nature 2018 publication).

3Politecnico di Torino
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration with Prof. Gianluca Ciardelli, Professor of Bionanotechnology in the Department of Mechanical and Aerospace Engineering. Joint research on 3D bioprinting of human adipose-derived stem cells and tenogenic differentiation.

sscf.ch
4Université de Marseille (Aix-Marseille University)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration with Prof. Guy Magalon (emeritus professor of plastic and reconstructive surgery) and Dr. Jeremy Magalon. Joint research on SVF standardization, scleroderma treatment, and adipose tissue processing devices.

sscf.ch
5University of Insubria (Varese, Italy)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration with Prof. Rosalba Gornati. Joint research on tenogenic differentiation of ASCs and chondrogenic differentiation. Also involved in PhD training programs.

sscf.ch
6LDM Laboratorio Diagnostica Molecolare (Lugano)
Strategic tierMajorTypeTechnology or Integration
Description

Collaboration with Dr. Mauro Gola (Director of Scientific Research, responsible for medical genetics). Joint work on molecular diagnostics and genetics related to stem cell therapies.

sscf.ch
7IRCCS Istituto Neurologico Carlo Besta (Milan)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Formal scientific agreement between IRCCS and SSCF for collaborative research in neurology and regenerative medicine.

sscf.ch
8PBL Parma (Italy)
Strategic tierSupportingTypeTechnology or Integration
Description

Collaboration with PBL Parma on automated robotic GMP laboratory technologies for stem cell processing.

sscf.ch
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic collaboration with University of Milan for research in regenerative medicine and stem cell therapies.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

International collaboration with Canadian biotech company Hemostemix on cell therapy research.

Strategic tierSupportingTypeTechnology or Integration
Description

Collaboration with US-based cell therapy company on technology and therapeutic applications.

12Tiger Biosciences (USA)
Strategic tierSupportingTypeTechnology or Integration
Description

Collaboration with US-based biosciences company on stem cell technologies.

sscf.ch
Strategic tierSupportingTypeOthers
Description

Host venue for Academy training courses and iCAST conferences. Partnership for delivery of hands-on training on adipose tissue harvesting and preparation for regenerative medicine. Course held February 28, 2024.

14Clinique Sant'Anna (Sorengo, Switzerland)
Strategic tierSupportingTypeOthers
Description

Host venue for Academy training courses. Partnership for delivery of hands-on mini-liposuction training workshop held July 19, 2024.

sscf.ch
Strategic tierSupportingTypeTechnology or Integration
Description

Technology partner for mechanical adipose tissue dissociation using the Lipocube device. Lipocube dedicated operator guided training during Academy courses on tissue processing technique.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global contract development and manufacturing organization with major cell and gene therapy manufacturing services. Comparable to SSCF's GMP-compliant SVF and MSC production capabilities, but at vastly greater scale and commercial breadth.

2EuroStemCell
TypeBroad incumbent
Description

UK-based center of excellence for cell and gene therapy development, including GMP manufacturing facilities and training. Comparable as a translational research and GMP manufacturing hub, though at much larger scale and with broader portfolio.

TypeEmerging player
Description

Manufacturer of GMP-grade cell culture reagents and cytokines used in cell and gene therapy manufacturing. Comparable to SSCF's GMP-compliant production focus, but specialized in raw materials rather than cell products.

TypeBroad incumbent
Description

Commercial provider of cell culture media, reagents, and tools for stem cell research. Operates in the same MSC research ecosystem as SSCF, supplying researchers with materials used in similar workflows.

6Pluristem Therapeutics
TypeEmerging player
Description

Clinical-stage cell therapy company using placenta-derived mesenchymal-like cells. Operates in overlapping MSC therapy space with similar therapeutic targets (critical limb ischemia, orthopedic indications).

TypeDirect peer
Description

State-funded research agency that funds and accelerates stem cell research and therapies in California. Comparable in mission (advancing stem cell science to clinical use) and structure (non-profit / public foundation), serving as a similar non-commercial model.

TypeDirect peer
Description

Canadian clinical-stage cell therapy company and a named collaborator of SSCF. Develops autologous cell therapies from blood and adipose tissue, working on overlapping therapeutic indications (critical limb ischemia, ischemic conditions).

TypeEmerging player
Description

Clinical-stage cell therapy company developing mesenchymal lineage cell therapies. Targets overlapping indications (cardiovascular, orthopedic) and works with the same MSC/SVF cell types as SSCF, but as a publicly funded commercial entity.

TypeDirect peer
Description

Independent non-profit research institute focused on stem cell research and translational applications. Most structurally similar peer to SSCF, both operating as foundations combining R&D, training, and community-building in stem cell science.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Swiss Stem Cell Foundation

Regenerative Medicine Researchsscf.ch

Swiss Stem Cell Foundation is a non-profit research foundation (est. 2009, Lugano, ~10 employees) that develops GMP-compliant adipose-derived stem cell therapies, operates an ethics-committee-authorized biobank, and delivers research services, cryopreservation, training courses, and the annual iCAST congress to clinicians and academic partners.

What Swiss Stem Cell Foundation does

Swiss Stem Cell Foundation (SSCF) is an independent, non-profit foundation established in 2009 in Lugano, Switzerland, with a research laboratory in Vacallo. It pursues research and development in adipose-derived mesenchymal stem cells (MSCs) and stromal vascular fraction (SVF), with the goal of developing new cell therapies for human medical use. Its core technical assets include GMP-compliant protocols for processing adipose tissue, MSC cryopreservation offering up to 30-year storage, MSC expansion for clinical use, exosome production and characterization, and the SSCF Research Biobank authorized by the Canton Ticino Ethics Committee (Rif. CE 2961). Notable scientific output includes a 2018 Nature publication (with EPFL and ETH Zurich) on aReg cells and twelve peer-reviewed publications in Medline-indexed journals; a China-granted patent covers the adipose tissue extraction process, and the SSCF brand is trademarked in the EU and China.

SSCF operates a hybrid GTM in which research services, GMP-compliant cell production, and cryopreservation services are delivered to surgical and clinical specialists (plastic surgeons, orthopedists, regenerative medicine practitioners), while international research collaborations with EPFL, ETH Zurich, Politecnico di Torino, Aix-Marseille University, University of Insubria, and IRCCS Besta distribute expertise and build scientific credibility. Revenue is generated through professional services (research and consultancy), GMP cryopreservation services, Academy training courses (CHF 450 per participant), and donations (with Certificates of Donation issued). The foundation runs the annual iCAST congress series since 2015 (9 editions) and Academy hands-on training programs at partner clinics (Clinique Genolier, Clinique Sant'Anna).

Major upcoming capacity is the Regenerative Medicine Institute — a 3,300 sqm applied research facility in the Lugano hospital district scheduled for completion by end of 2025, designed to accommodate GMP clean rooms, genetics labs, diagnostics labs, biobanking facilities, and lab space for approximately 50 researchers. The foundation is governed by a Board of Foundation Members and a Scientific Committee, with Dr. Gianni Soldati serving as President and Director of Research.

Swiss Stem Cell Foundation firmographics

Firmographics
Name
Swiss Stem Cell Foundation
Legal name
Swiss Stem Cell Foundation
Website
https://sscf.ch
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Swiss Stem Cell Foundation is a non-profit research foundation (est. 2009, Lugano, ~10 employees) that develops GMP-compliant adipose-derived stem cell therapies, operates an ethics-committee-authorized biobank, and delivers research services, cryopreservation, training courses, and the annual iCAST congress to clinicians and academic partners.
Ownership category
akta.pro rank

Swiss Stem Cell Foundation industry classification

Industry
Product category
Regenerative Medicine Research
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Grantmaking Foundations (813211)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Services-Educational Services (8200)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYBPAGAKAA
Private Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Stem cell research
  • Regenerative medicine
  • Cell therapy services
  • GMP cell processing
  • Medical research education

Where Swiss Stem Cell Foundation is headquartered

Location

Headquarters

HQ city
Lugano
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Swiss Stem Cell Foundation business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Others, Marketing or Sales

Revenue model

  1. Research services and consultancy: Provision of services in analysis and research domains, including consultancy through qualified professionals on new products, tools, medical devices, and therapies. As a non-profit foundation, revenues support research and development activities.
  2. GMP cryopreservation services: Cryopreservation of adipose-derived mesenchymal stem cells as a service for future medical needs, including GMP-compliant processing of SVF for clinical use.
  3. Education and training programs: Organization and delivery of Academy courses and professional training for healthcare operators on stem cell therapies and adipose tissue handling. Course fees (e.g., CHF 450 per participant) contribute to operational funding.
  4. Donations and charitable contributions: The foundation accepts donations to support stem cell research and development of new stem cell therapies, issuing Certificates of Donation to contributors.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAcademy training course fee

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Swiss Stem Cell Foundation product offering

Product offering

Core offering

The Swiss Stem Cell Foundation is an independent non-profit foundation pursuing research and development in stem cells, focused on adipose-derived mesenchymal stem cells (MSCs) and stromal vascular fraction (SVF). It provides GMP-compliant isolation, characterization, cryopreservation, and expansion services for MSCs, operates an ethics-committee-authorized research biobank, and develops new cell therapies for human medical use. The foundation also delivers professional training through its Academy program and disseminates knowledge via the annual iCAST international congress on adipose stem cell treatments.

Product overview

The Swiss Stem Cell Foundation operates as a non-profit research foundation offering a portfolio of stem cell research and development services. The core offering centers on the SSCF Research Biobank for sample storage and the GMP-compliant production of mesenchymal stem cell products and adipose-derived stromal vascular fraction for cell therapies. Additional services include MSC cryopreservation, expansion for clinical use, and exosome characterization. The Foundation organizes the annual iCAST Congress Series (International Congress on Adipose Stem Cell Treatments) since 2015 and Academy training programs for professionals. A major upcoming development is the Regenerative Medicine Institute—a 3,300 sqm facility with GMP laboratories, biobanking spaces, and conference facilities planned for completion in 2025.

Differentiator

Problem solved

Functional benefit

Brands

  • SSCF: Abbreviated name used for Swiss Stem Cell Foundation in communications and materials.
  • SSCF Research Biobank

Products and services

  • SSCF Research Biobank Research biobank authorized by the Canton Ticino Ethics Committee (Ref CE 2961) providing pre-clinical research services including collection, storage, and characterization of mesenchymal stromal/stem cell samples from adipose tissue. Enables development of methodologies and technologies for isolation, characterization, and large-scale production of mesenchymal stromal/stem cells for research projects and future cell therapies in human medicine.

Quantifiable outcome

  • 364 GMP-compliant SVF productions across multiple centers in a standardization study
  • +1 more outcomes

Companies that use Swiss Stem Cell Foundation

Customer profile

Segments3 records

Ideal customer profiles3 records

Swiss Stem Cell Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Swiss Stem Cell Foundation partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core, major and supporting.

  • EPFL (Ecole Polytechnique Fédérale de Lausanne)coreStrategic or Co-development PartnerCollaboration with Dr. Bart Deplancke's Laboratory of Systems Biology and Genetics at EPFL. Joint project on single-cell characterization of SVF populations and sub-populations. Resulted in Nature publication (2018) on aReg cells. Ongoing collaboration for characterization of substances produced by aReg cells.
  • ETH ZurichcoreStrategic or Co-development PartnerCollaborated with ETH Zurich alongside EPFL in the identification of aReg cell populations in adipose tissue (Nature 2018 publication).
  • Politecnico di TorinomajorStrategic or Co-development PartnerCollaboration with Prof. Gianluca Ciardelli, Professor of Bionanotechnology in the Department of Mechanical and Aerospace Engineering. Joint research on 3D bioprinting of human adipose-derived stem cells and tenogenic differentiation.
  • Université de Marseille (Aix-Marseille University)majorStrategic or Co-development PartnerCollaboration with Prof. Guy Magalon (emeritus professor of plastic and reconstructive surgery) and Dr. Jeremy Magalon. Joint research on SVF standardization, scleroderma treatment, and adipose tissue processing devices.
  • University of Insubria (Varese, Italy)majorStrategic or Co-development PartnerCollaboration with Prof. Rosalba Gornati. Joint research on tenogenic differentiation of ASCs and chondrogenic differentiation. Also involved in PhD training programs.
  • LDM Laboratorio Diagnostica Molecolare (Lugano)majorTechnology or IntegrationCollaboration with Dr. Mauro Gola (Director of Scientific Research, responsible for medical genetics). Joint work on molecular diagnostics and genetics related to stem cell therapies.
  • IRCCS Istituto Neurologico Carlo Besta (Milan)majorStrategic or Co-development PartnerFormal scientific agreement between IRCCS and SSCF for collaborative research in neurology and regenerative medicine.
  • PBL Parma (Italy)supportingTechnology or IntegrationCollaboration with PBL Parma on automated robotic GMP laboratory technologies for stem cell processing.
  • University of Milan (UNIMI)supportingStrategic or Co-development PartnerAcademic collaboration with University of Milan for research in regenerative medicine and stem cell therapies.
  • Hemostemix (Calgary, Canada)supportingStrategic or Co-development PartnerInternational collaboration with Canadian biotech company Hemostemix on cell therapy research.
  • Ambrose Cell Therapy (Los Angeles, USA)supportingTechnology or IntegrationCollaboration with US-based cell therapy company on technology and therapeutic applications.
  • Tiger Biosciences (USA)supportingTechnology or IntegrationCollaboration with US-based biosciences company on stem cell technologies.
  • Clinique Genolier (Genolier, Switzerland)supportingOthersHost venue for Academy training courses and iCAST conferences. Partnership for delivery of hands-on training on adipose tissue harvesting and preparation for regenerative medicine. Course held February 28, 2024.
  • Clinique Sant'Anna (Sorengo, Switzerland)supportingOthersHost venue for Academy training courses. Partnership for delivery of hands-on mini-liposuction training workshop held July 19, 2024.
  • LipocubesupportingTechnology or IntegrationTechnology partner for mechanical adipose tissue dissociation using the Lipocube device. Lipocube dedicated operator guided training during Academy courses on tissue processing technique.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Swiss Stem Cell Foundation competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Global contract development and manufacturing organization with major cell and gene therapy manufacturing services. Comparable to SSCF's GMP-compliant SVF and MSC production capabilities, but at vastly greater scale and commercial breadth.
  • Cell & Gene Therapy Catapult: UK-based center of excellence for cell and gene therapy development, including GMP manufacturing facilities and training. Comparable as a translational research and GMP manufacturing hub, though at much larger scale and with broader portfolio.
  • STEMCELL Technologies: Commercial provider of cell culture media, reagents, and tools for stem cell research. Operates in the same MSC research ecosystem as SSCF, supplying researchers with materials used in similar workflows.

Peers

  • EuroStemCell:

Emerging players

  • CellGenix: Manufacturer of GMP-grade cell culture reagents and cytokines used in cell and gene therapy manufacturing. Comparable to SSCF's GMP-compliant production focus, but specialized in raw materials rather than cell products.
  • Pluristem Therapeutics: Clinical-stage cell therapy company using placenta-derived mesenchymal-like cells. Operates in overlapping MSC therapy space with similar therapeutic targets (critical limb ischemia, orthopedic indications).
  • Mesoblast: Clinical-stage cell therapy company developing mesenchymal lineage cell therapies. Targets overlapping indications (cardiovascular, orthopedic) and works with the same MSC/SVF cell types as SSCF, but as a publicly funded commercial entity.

Direct peers

  • California Institute for Regenerative Medicine (CIRM): State-funded research agency that funds and accelerates stem cell research and therapies in California. Comparable in mission (advancing stem cell science to clinical use) and structure (non-profit / public foundation), serving as a similar non-commercial model.
  • Hemostemix: Canadian clinical-stage cell therapy company and a named collaborator of SSCF. Develops autologous cell therapies from blood and adipose tissue, working on overlapping therapeutic indications (critical limb ischemia, ischemic conditions).
  • New York Stem Cell Foundation: Independent non-profit research institute focused on stem cell research and translational applications. Most structurally similar peer to SSCF, both operating as foundations combining R&D, training, and community-building in stem cell science.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks1 record

Key highlights7 records

Customer concentration

Swiss Stem Cell Foundation social profiles

Digital presence

Swiss Stem Cell Foundation compliance and trust

Trust signal

Compliance4 records

Swiss Stem Cell Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Swiss Stem Cell Foundation leadership team

Management profile

Number of profiles

Profiles8 records

Swiss Stem Cell Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Swiss Stem Cell Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Swiss Stem Cell Foundation

What does Swiss Stem Cell Foundation do?

The Swiss Stem Cell Foundation is an independent non-profit foundation pursuing research and development in stem cells, focused on adipose-derived mesenchymal stem cells (MSCs) and stromal vascular fraction (SVF). It provides GMP-compliant isolation, characterization, cryopreservation, and expansion services for MSCs, operates an ethics-committee-authorized research biobank, and develops new cell therapies for human medical use. The foundation also delivers professional training through its Academy program and disseminates knowledge via the annual iCAST international congress on adipose stem cell treatments.

Is Swiss Stem Cell Foundation a public or private company?

Swiss Stem Cell Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Swiss Stem Cell Foundation founded?

Swiss Stem Cell Foundation was founded in 2009. It employs 1 to 10 people.

Where is Swiss Stem Cell Foundation based?

Swiss Stem Cell Foundation is headquartered in Lugano, Switzerland, in the Europe region.

How does Swiss Stem Cell Foundation make money?

Four revenue lines are on record. Research services and consultancy is the primary driver. The others are GMP cryopreservation services, education and training programs and donations and charitable contributions.

Who are Swiss Stem Cell Foundation's main competitors?

Broad incumbents on record are Lonza Group, Cell & Gene Therapy Catapult and STEMCELL Technologies. EuroStemCell is listed as a peer. Emerging players are CellGenix, Pluristem Therapeutics and Mesoblast. Direct peers are California Institute for Regenerative Medicine (CIRM), Hemostemix and New York Stem Cell Foundation.

Does Swiss Stem Cell Foundation have an API?

No public API is recorded for Swiss Stem Cell Foundation.

What industry is Swiss Stem Cell Foundation in?

Swiss Stem Cell Foundation's product category is Regenerative Medicine Research. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of BPAGAKAA, Private Foundations. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales